» Articles » PMID: 39972461

What Have We Learned from Long-term Studies in Juvenile Idiopathic Arthritis? - Prediction, Classification, Transition

Overview
Publisher Biomed Central
Specialty Pediatrics
Date 2025 Feb 19
PMID 39972461
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Research and management of juvenile idiopathic arthritis (JIA) are challenging due to its heterogeneous nature, chronicity, and unpredictable, multidimensional long-term outcomes.

Main Body: Long-term studies have consistently shown that a majority of children with JIA reach adulthood with ongoing disease activity, on medication, or with recurrent flares. The heterogeneity is evident both between and within the present JIA categories based on The International League of Associations for Rheumatology (ILAR) JIA classification system. Several baseline predicting factors are known, but prediction modelling is only in the initial phase, and more models need to be tested in independent cohorts and possibly also supplemented with new biomarkers. Many have criticized the ILAR classification system, but new or updated classification systems have not yet been validated and proved their superiority. The lack of prediction possibilities for long-term outcomes and the limited alignment between JIA classification categories and adult rheumatic conditions are challenges for research, may limit the accessibility to treatment, and hamper a smooth transition to adult care.

Conclusion: We need more prospective, long-term studies based on unselected JIA cohorts with disease onset in the biologic era that can aid decision-making for individualized early treatment, suggest intervention studies, and ensure our patients the best possible transition to adulthood and the best likelihood of optimal health and quality of life.

References
1.
Courvoisier D, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J . The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford). 2020; 60(2):820-828. DOI: 10.1093/rheumatology/keaa393. View

2.
Nordal E, Rypdal V, Christoffersen T, Aalto K, Berntson L, Fasth A . Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study. Pediatr Rheumatol Online J. 2017; 15(1):66. PMC: 5562983. DOI: 10.1186/s12969-017-0195-8. View

3.
Rypdal V, Arnstad E, Aalto K, Berntson L, Ekelund M, Fasth A . Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: results from the Nordic cohort study. Arthritis Res Ther. 2018; 20(1):91. PMC: 5934822. DOI: 10.1186/s13075-018-1571-6. View

4.
Oliveira Ramos F, Zinterl C, Fonseca J . A lifelong journey: Long-term perspectives on Juvenile Idiopathic Arthritis. Best Pract Res Clin Rheumatol. 2024; 38(3):101984. DOI: 10.1016/j.berh.2024.101984. View

5.
Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V . Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol. 2003; 30(2):386-93. View